Avadel Pharmaceuticals (AVDL) Competitors $8.89 +0.28 (+3.25%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVDL vs. AKRO, MRUS, MOR, SRRK, PTGX, CRNX, SWTX, OGN, CPRX, and VKTXShould you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Avadel Pharmaceuticals vs. Akero Therapeutics Merus MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Akero Therapeutics (NASDAQ:AKRO) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk. Do institutionals and insiders hold more shares of AKRO or AVDL? 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 7.9% of Akero Therapeutics shares are owned by insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, AKRO or AVDL? Akero Therapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Do analysts prefer AKRO or AVDL? Akero Therapeutics presently has a consensus target price of $76.29, suggesting a potential upside of 67.26%. Avadel Pharmaceuticals has a consensus target price of $19.88, suggesting a potential upside of 123.57%. Given Avadel Pharmaceuticals' higher probable upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to AKRO or AVDL? In the previous week, Akero Therapeutics had 8 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 12 mentions for Akero Therapeutics and 4 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 1.79 beat Akero Therapeutics' score of 1.21 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avadel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable valuation and earnings, AKRO or AVDL? Akero Therapeutics has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$3.75-12.16Avadel Pharmaceuticals$169.12M5.08-$160.28M-$0.52-17.10 Is AKRO or AVDL more profitable? Akero Therapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. Akero Therapeutics' return on equity of -32.46% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Avadel Pharmaceuticals -52.53%-93.34%-44.77% Does the MarketBeat Community favor AKRO or AVDL? Avadel Pharmaceuticals received 233 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 66.54% of users gave Avadel Pharmaceuticals an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% Avadel PharmaceuticalsOutperform Votes35066.54% Underperform Votes17633.46% SummaryAvadel Pharmaceuticals beats Akero Therapeutics on 9 of the 16 factors compared between the two stocks. Get Avadel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVDL vs. The Competition Export to ExcelMetricAvadel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$859.03M$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-11.257.4422.4418.48Price / Sales5.08242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book9.076.516.774.25Net Income-$160.28M$143.21M$3.22B$248.23M7 Day Performance3.37%1.98%1.49%0.89%1 Month Performance18.38%6.89%4.00%3.53%1 Year Performance-51.45%-2.52%16.21%5.08% Avadel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVDLAvadel Pharmaceuticals2.303 of 5 stars$8.89+3.3%$19.88+123.6%-51.0%$859.03M$169.12M-11.2570Upcoming EarningsPositive NewsAKROAkero Therapeutics3.7928 of 5 stars$37.67+0.1%$76.29+102.5%+129.3%$3.00BN/A-10.0530Insider TradeNews CoveragePositive NewsMRUSMerus3.4404 of 5 stars$43.23+0.4%$85.31+97.3%+1.3%$2.99B$36.13M-10.9437Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionPositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0498 of 5 stars$29.81-3.1%$42.67+43.1%+124.3%$2.83B$33.19M-12.69140Upcoming EarningsInsider TradeNews CoveragePositive NewsPTGXProtagonist Therapeutics3.4277 of 5 stars$45.80-1.0%$65.44+42.9%+82.5%$2.81B$434.43M17.22120Upcoming EarningsPositive NewsCRNXCrinetics Pharmaceuticals3.6653 of 5 stars$30.15-0.9%$73.00+142.1%-23.8%$2.81B$1.04M-8.08210Upcoming EarningsPositive NewsSWTXSpringWorks Therapeutics1.9516 of 5 stars$37.06-2.3%$73.20+97.5%-0.8%$2.78B$191.59M-10.65230Analyst ForecastNews CoverageOGNOrganon & Co.4.7679 of 5 stars$10.67-4.0%$20.60+93.1%-30.5%$2.75B$6.40B3.2010,000Positive NewsCPRXCatalyst Pharmaceuticals4.6879 of 5 stars$22.02-2.2%$32.29+46.6%+61.4%$2.69B$491.73M18.6680Upcoming EarningsNews CoveragePositive NewsVKTXViking Therapeutics4.4778 of 5 stars$23.72-0.9%$89.75+278.4%-63.7%$2.66BN/A-23.7220Analyst ForecastOptions VolumeAnalyst Revision Related Companies and Tools Related Companies AKRO Competitors MRUS Competitors MOR Competitors SRRK Competitors PTGX Competitors CRNX Competitors SWTX Competitors OGN Competitors CPRX Competitors VKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVDL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVDL Stock Free AVDL Stock Alerts